Dear Colleague,

For more than 117 years, physicians, scientists and staff at National Jewish Health have focused on patients with respiratory disease. Based in Colorado, we recently opened the Mount Sinai — National Jewish Health Respiratory Institute in New York City in partnership with the Icahn School of Medicine at Mount Sinai.

At National Jewish Health, our team of expert pulmonologists conducts intensive, evaluations in collaboration with cardiologists, gastroenterologists, allergists, oncologists, immunologists and others on the National Jewish Health staff. Once we develop a diagnosis and a treatment plan, we then work with patients’ hometown physicians to implement the plan and adjust care as necessary.

Our unparalleled care is backed by a robust research program that ranges from basic discovery to translational and clinical research. Our faculty, outstanding leaders in their fields, also train medical students, residents and postgraduate fellows in affiliation with the University of Colorado School of Medicine. Established physicians learn from our experts at conferences and in continuing medical education.

At National Jewish Health, our intense focus on respiratory disease — in patient care, research and education — positions us as leaders in pulmonary medicine. This publication, “National Jewish Health Pulmonary Highlights 2015,” captures the state of pulmonary medicine at National Jewish Health — what we are working on, what we have learned and where we are headed. We hope you will find it informative and relevant to your own practice.

Richard J. Martin, MD
Chair, Department of Medicine
National Jewish Health

Irina Petrache, MD
Chief, Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Clinical Expertise

With 117 years of singular attention to respiratory disease, National Jewish Health provides unparalleled care for complex, symptomatic pulmonary patients. In one multi-day stay, patients from around the nation see our expert pulmonary subspecialists and their colleagues in cardiology, gastroenterology, oncology, immunology and radiology for evaluations, diagnoses and treatment plans.

Asthma
Thorough upper and lower airway evaluations in our multi-day adult and pediatric asthma programs help us phenotype patients and tease out complicating factors from aspiration to allergies, vocal cord dysfunction and inhaler technique. Our faculty members lead numerous NIH studies and industry-sponsored clinical trials.

Cardiology
Our cardiologists are experts in the heart-lung interface. They work closely with pulmonologists to diagnose and treat the cardiac causes and consequences of lung disease, including pulmonary hypertension, cardiac sarcoidosis and other rare diseases.

COPD
A complete medical and non-medical evaluation allows our team of physicians and therapists to address not only COPD medications, but also education, compliance, nutrition, and rehabilitation. Personalized management plans and education optimize care and quality of life. Our faculty is advancing pulmonary medicine with COPDGene and other studies to diagnose and phenotype COPD.

NTM
Mycobacterial disease is part of our DNA, with our origins as a hospital for destitute tuberculosis patients. The longevity of our program and our experience with thousands of complex mycobacterial infections have given us a deep knowledge of antibiotic regimens and surgical options. In addition to our intensive outpatient program, we provide inpatient care and surgical support through our new collaborative relationship with Saint Joseph Hospital.

Cystic Fibrosis
We have the largest adult cystic fibrosis program in the nation. Our team of pulmonary specialists, nurse coordinators, respiratory therapists, registered dietitians and social workers provides treatment for more than 400 adults. We have more than two dozen ongoing clinical trials to evaluate new cystic fibrosis therapies.

Chronic Beryllium Disease
National Jewish Health has more experience with the diagnosis and treatment of beryllium disease than any other group in the world. We emphasize early disease detection and intervention to halt or slow disease progression. We have published extensively on exposures, genetic factors and immune responses associated with chronic beryllium disease.

Environmental Health
In step with increasing recognition that environmental pollutants cause disease, our multidisciplinary team has
helped define, diagnose and treat patients with a broad range of occupational, environmental and granulomatous lung diseases. Our thorough evaluations have uncovered previously unknown causes of pulmonary disease.

**Interstitial Lung Disease**
We have vast experience with interstitial lung disease (ILD). A detailed evaluation, diagnosis and plan of care are based on the most current information about ILD, much of which has been discovered at National Jewish Health. We have ongoing trials of approved and experimental medications. We seek to broaden knowledge of ILD causes and develop new treatments.

**Oncology**
Expert pulmonologists, thoracic radiologists and gastroenterologists help us diagnose and treat cancers of the lungs, head and neck, and digestive system. Lung cancer screening and our tumor registry help us screen and monitor patients at high risk for lung cancer.

**Pediatrics**
For decades we have helped shape the evolving knowledge about diagnosis and treatment of asthma, vocal cord dysfunction, and other pediatric pulmonary diseases. Our Severe Asthma Clinic and Pediatric Day Program offer multi-day medical and psychological evaluations, education and management plans for children with pulmonary and atopic diseases.

**Sarcoidosis**
Support from our expert cardiologists, neurologists and network of providers positions National Jewish Health to address the multi-organ nature of sarcoidosis. Our experience with thousands of sarcoidosis patients has helped us better define the disease and gain insight into its causes.

**Diagnostic Laboratories**
The Advanced Diagnostic Laboratories have CAP15189 accreditation and decades of experience developing immunology, complement, infectious disease and molecular diagnostic tests. We help clients select, customize and interpret laboratory tests from around the world.

**Pulmonary Physiology Services**
Our state-of-the-art laboratory offers many unique tests, including exercise-induced bronchoconstriction; cardiopulmonary exercise test with full metabolic testing, arterial line, lactate levels, and cardiac data; and continuous laryngoscopy with exercise tolerance.

**Interventional Pulmonology**
Our minimally invasive diagnostic, therapeutic and palliative procedures include identification, diagnosis and treatment of pulmonary nodules; early detection of lung cancer; diagnosis and treatment of airway obstructions; pleural procedures; implantation and removal of airway stents and bronchial thermoplasty.

---

**MOUNT SINAI – NATIONAL JEWISH HEALTH RESPIRATORY INSTITUTE**
The Icahn School of Medicine at Mount Sinai, a leading academic medical center in New York City, and National Jewish Health have partnered to create the Mount Sinai – National Jewish Health Respiratory Institute in New York City. The Respiratory Institute brings together leading experts in diagnosing and treating respiratory disease and offers a model for multidisciplinary, personalized care for patients with respiratory disease.

---

**Mount Sinai - National Jewish Health Respiratory Institute**

---

National Jewish Health
Clinical Research

National Jewish Health is constantly searching for new, more effective treatments and medications for our patients and patients around the world. Today, we have more than 300 active clinical trials that offer cutting-edge, experimental treatments for a wide range of respiratory and related diseases. We collaborate with the National Institutes of Health, industry and leading research institutions across the nation as members of numerous research networks and consortiums.

SELECTED 2015 CLINICAL RESEARCH RESULTS

Tiotropium a Reasonable Alternative to LABAs in Asthma

Tiotropium, an anti-cholinergic recently approved for use in asthma, offers a potential alternative to long-acting beta agonists (LABAs), whose safety, especially in African Americans, has been under a cloud of suspicion for several years. Michael Wechsler, MD, and his colleagues reported that tiotropium and various LABAs used for up to 18 months performed similarly in 1,107 black adults with asthma for time to first exacerbation, change in FEV1 and various patient-reported outcomes. The tiotropium group did suffer more hospitalizations (19) than the LABA group (10). However, due to study design, that difference was not considered statistically significant. *JAMA* 2015:314(16)

Elizabeth A. Regan, MD, James D. Crapo, MD, and their colleagues evaluated 8,872 people ages 45 to 80 with at least a 10 pack-year history, about half of whom were considered disease-free. When the researchers considered other criteria, they found that 55 percent of the disease-free study participants had some form of respiratory related impairment. CT scans found emphysema or airway thickening in 42 percent of the disease-free participants. Twenty-three percent had significant shortness of breath compared to 3.7 percent of never smokers. Fifteen percent walked less than 350 meters in six minutes, compared to 4 percent of never smokers. Twenty-five percent had clinically significant reductions in quality of life. *JAMA Intern Med. 2015:175(9)*

Normal Spirometry, Undiagnosed Lung Disease

More than half of long-term smokers and ex-smokers considered disease-free, based on spirometry results, have respiratory-related impairments when evaluated with imaging, functional and quality-of-life tests. Phosphodiestrase inhibitors, such as sildenafil (Viagra®), have been shown to have inflammatory activity. They also may potentiate potential CFTR-mediated chloride transport in respiratory and digestive tissues. Jennifer Taylor-Cousar, MD, Jerry Nick, MD, and their colleagues reported that 20 mild to moderate cystic fibrosis patients tolerated oral sildenafil 3 times a day with generally mild side effects and no drug-related serious adverse events. Cystic fibrosis patients eliminated sildenafil more rapidly than healthy subjects did. Sputum neutrophil elastase activity, a surrogate biomarker response to therapy, was also reduced. Sildenafil warrants further study as an anti-inflammatory in cystic fibrosis. *J Cyst Fibros 2015:14(2)*.

For additional research publications, see page 12.
Clinical Research

SELECTED OPEN CLINICAL TRIALS

COPD
PI: James Crapo, MD
COPDGene – Genetic Epidemiology of COPD.

PI: Barry Make, MD
Prostaglandin Inhibition for Emphysema (Pie)

Asthma
PI: Richard Martin, MD
Identification of Molecular Biomarkers to Stratify Patients with Refractory Asthma
Airway and Gut Microbiome in Allergy and Asthma: Relationships to Immune and Clinical Phenotype.

PI: Kendra Hammond, MD
A Prospective Observational Study of Biopredictors of Bronchial Thermoplasty Response in Patients with Severe Refractory Asthma

Interstitial Lung Disease
PI: Kevin K. Brown, MD
Lung Tissue Research Consortium Protocol

PI: Jeff Swigris, DO
Observing the Effects of Supplemental Oxygen on Patients with Pulmonary Fibrosis

Sarcoidosis
PI: Nabeel Hamzeh, MD
Role of TH17 and MCAM Positive Cells in Sarcoidosis
Association of Auto-Antibodies with Extra-Pulmonary Sarcoidosis

Churg Strauss Syndrome
PI: Michael Wechsler, MD
Anti-IL5 and Churg Strauss Syndrome

Cystic Fibrosis
PI: Jerry Nick, MD
Early Intervention in Cystic Fibrosis Exacerbation

Prospective Evaluation of Nontuberculous Mycobacterial Disease in Cystic Fibrosis (Predict) Trial

PI: Milene Saavedra, MD
Ultrasensitive Detection of Reductions in CF Airway Inflammation

Non-Tuberculosis Mycobacterial Disease
PI: Edward Chan, MD
Resistance of Nontuberculous Mycobacteria to the Cathelicidin Antibacterial Peptide
Determining the Phenotype and Genotype that Predisposes to Non-Tuberculous Mycobacterial Lung Disease

Other
PI: Russell Bowler, MD
Colorado Marijuana Users Health Cohort

PI: Evans Fernandez-Perez, MD
Peripheral Blood Mononuclear Cell Gene Expression Profiles in Chronic Hypersensitivity
In the laboratory, scientists at National Jewish Health are advancing the frontiers of pulmonary science. Working closely with physicians, who provide crucial insights and questions from clinical experience, our scientists are delving deeply into the genetics and epigenetics of lung disease, the fundamental mechanisms of lung injury and repair, and the immunological function of the lungs. The answers they find will inspire the therapies of tomorrow.

SELECTED 2015 RESEARCH REPORTS

**CRISPR-Cas9 Gene Knockout in Epithelial Cells**
Epithelial cells in the lungs serve as the first line of defense against inhaled environmental hazards such as pathogens and pollutants. Knockout of single genes in these cells would allow better analysis of the epithelial response to environmental insults. The powerful CRISPR-Cas9 gene editing technology has been used to edit single genes in transformed, pluripotent and mouse cells, but not human primary epithelial cells. Max Seibold, PhD, and his colleagues used lentiviral delivery of the CRISPR-Cas9 machinery and modified culture conditions to successfully knock out the MUC18 gene in airway epithelial cells. The knock out indicated that MUC18 contributes to airway inflammation. More significantly, the methods developed by Seibold and colleagues contribute a valuable tool for genetic studies of disease processes. *Gene Therapy* 2015:20(10)

**Microbiome Study Identifies Biomarker for Steroid Resistance**
Corticosteroids are the most commonly prescribed controller medication for millions of asthma patients. However, an estimated 20 percent to 30 percent of asthma patients do not respond to corticosteroids. An effective biomarker for steroid resistance could help identify patients resistant to steroids and avoid ineffective treatments. Studies by Donald Leung, MD, PhD, and Elena Goleva, MD, of the microbiome and Vitamin D in cells from steroid resistant patients pointed to the inflammatory p38 MAPK pathway as an active participant in the response to steroids. In October 2015, they reported findings identifying activation of the p38 MAPK pathway in peripheral blood monocytes as a promising biomarker for corticosteroid resistance. Patents have been applied for. *Plos ONE* 2015:10(10)

**Obesity as Risk Factor For Influenza Infection**
Human alveolar epithelial cells (AEC) and alveolar macrophages are the first lines of lung defense. Emily Travanty, PhD, Robert Mason, MD, and their colleagues reported that alveolar epithelial cells are more susceptible to infection by H1N1 viruses, but that macrophages release higher levels of cytokines. Gender, age and smoking history did not affect susceptibility, but epithelial cells from obese individuals were more susceptible to H1N1 infection. Variants of the H1N1 virus responsible for the 2009 pandemic showed slight differences in infectivity. The variations in infectivity were traced to a single amino acid substitution in the hemagglutinin protein. *J Virol.* 2015:89(23)

For additional research publications, see page 12.
Frontiers of Pulmonary Science

NOTEWORTHY ONGOING RESEARCH

**PI: Hong W. Chu**
IRAK-M in lung defense against rhinovirus infection

**PI: Rachel L. Zemans**
Mechanisms of alveolar epithelial repair in lung injury

**PI: William J. Janssen**
Macrophage apoptosis in resolution of acute lung injury

**PI: Irina Petrache**
Ceramide-induced lung destruction in emphysema

**PI: Gregory P. Downey**
Targeting PTPalpha to prevent lung fibrosis

**PI: Peter M. Henson**
Macrophage endocytosis in resolving lung inflammation

**PI: Magdalena Gorska**
Asthma susceptibility due to environmental programming of innate immunity in utero

**PI: Stijn DeLanghe**
Role of WNT and FGF signaling in alveolar epithelial regeneration after bleomycin injury

RECENT PATENTS

Methods and Compositions for the Disruption of Biofilms (pat. no. 8,901,167)

**Inventors: Jerry Nick, Travis Walker, Scott Worthen**

Methods to Determine Susceptibility to Treatment with Leukotriene Modifiers (pat. no. 8,685,740)

**Inventors: Nathan Rabinovitch, Erwin Gelfand**

Therapeutic Compositions and Methods for the Prevention of Autoimmune Diseases (pat. no. 8,673,300)

**Inventors: George Eisenbarth, Li Zhang, John Kappler, Brian Stadinski**

Methods and Compositions for Risk Prediction, Diagnosis, Prognosis and Treatment of Pulmonary Disorders (pat. no. 8,673,565)

**Inventors: David Schwartz, Max Seibold**

PRECISION MEDICINE AT NATIONAL JEWISH HEALTH

Precision, or personalized, medicine has been a central element of our approach to patient care and research since 2007. We have invested heavily in the tools of precision medicine, from the Institute for Advanced Biomedical Imaging, to the Integrated Bioinformation and Specimen Center, the Center for Genes Environment and Health, the Minimally Invasive Diagnostic Center and Advanced Diagnostic Laboratories.

In the clinic, our thorough evaluations seek to phenotype patients so we can prescribe more effective, targeted therapies. We have developed new tests to predict patients’ response to therapy in cystic fibrosis, asthma and other diseases. Genetic testing guides our cancer treatment.

Research such as COPDGene, a genetic epidemiological study we co-lead of 10,000 smokers, seeks to identify new phenotypes that are more amenable to treatment. Researchers are discovering new genetic and epigenetic causes of lung disease. Clinical trials evaluate targeted therapies and identify phenotypes responsive to those medications.
Education

ACADEMIC TRAINING
National Jewish Health physicians and scientists are thought leaders in their fields providing fellowships and training, which serve to elevate the standard of patient care and teach the next generation of health professionals. National Jewish Health is an accredited teaching affiliate of the University of Colorado School of Medicine, where our physicians and scientists have faculty appointments.

Clinical Fellowships
In collaboration with the University of Colorado School of Medicine, National Jewish Health offers several fellowship programs.

Based at National Jewish Health:
• Adult Sleep Medicine
• Pediatric Allergy and Immunology
• Adult Allergy and Immunology
• Mycobacterial Disease

Based at University of Colorado School of Medicine with rotations at National Jewish Health:
• Adult Pulmonary and Critical Care Medicine
• Infectious Disease
• Pediatric Pulmonary Medicine
• Rheumatology
• Cardiothoracic Radiology

In collaboration with the Colorado School of Public Health, National Jewish Health also offers fellowships in:
• Occupational and Environmental Medicine

Postdoctoral Fellowships
National Jewish Health has a robust discovery and translation research enterprise, placing National Jewish Health in the top 6 percent of institutions funded by the National Institutes of Health. Numerous opportunities exist for postdoctoral training in laboratories in the Department of Biomedical Research, the Division of Cell Biology and the Basic Science Section of the Department of Medicine.

Graduate Education
Students who are enrolled in one of the PhD programs offered by the Graduate School of the University of Colorado Denver, have the opportunity to perform their thesis research in the laboratories of the faculty at National Jewish Health.

Residents and Medical Students
Residents and medical students at the University of Colorado School of Medicine have rotations at National Jewish Health in a variety of specialties including pulmonary medicine, cardiology, allergy and gastroenterology.
CONTINUING MEDICAL EDUCATION

National Jewish Health offers a diverse and robust curriculum for continuing medical education both, live and online. Below are a few of the course offerings.

**The 53rd Semi-Annual Denver TB Course April 2016**
April 6-9, 2016, National Jewish Health, Denver, CO
The Denver TB Course, offered every year in April and October, provides a broad overview of active and latent TB, including its epidemiology, transmission, pathogenesis, diagnosis, treatment and management. This course presents this body of knowledge to any health care providers who will be responsible for the management and care of patients with tuberculosis.

**39th Annual Pulmonary & Allergy Update at Keystone**
February 1-4, 2017, Dillon, CO
The Pulmonary and Allergy Update highlights insights and recent advances in pulmonary medicine, asthma, allergy and immunology, presented by faculty from the leading respiratory hospital in the nation. Network with colleagues and nationally recognized experts, and learn the latest updates on management and treatment options for your patients. Workshops and small group sessions provide great opportunities to discuss key issues and interesting cases with colleagues and National Jewish Health faculty.

**Online Courses**

**Asthma**: Supraglottic Index Learning Program

**Managing COPD**: The Evolving Therapeutic Paradigm and Patient Education

**Optimizing Cystic Fibrosis Nutrition Outcomes**: A Multidisciplinary Approach to Pancreatic Insufficiency

**The Pharmacist’s Role** in Navigating the Expanding Treatment Armamentarium and Practice-Changing Advances in Cystic Fibrosis

**Addressing the Burden of Clostridium difficile Infection**: A Contemporary Assessment of Strategies for Prevention and Treatment

**Idiopathic Pulmonary Fibrosis in Evolution**: Proactive Recognition, Early Diagnosis, and an Advancing Standard of Care

**Advanced NSCLC Case Round-Up**: Emerging Strategies in Personalized Care

For more information about our courses please call 800.844.2305 or visit www.nationaljewish.org/professionals/education/pro-ed/overview.
Faculty Leadership

DEPARTMENT OF MEDICINE
Richard J. Martin, MD, Chair
Kevin K. Brown, MD, Vice Chair of Clinical Affairs
Brian J. Day, PhD, Vice Chair of Research
Jeffrey A. Kern, MD, Vice Chair of Finance

Division of Pulmonary, Critical Care and Sleep Medicine
Irina Petrache, MD, Chief

Division of Allergy and Clinical Immunology
Rafeul Alam, MD, PhD, Chief

Division of Cardiology
J. Kern Buckner, MD, Chief

Community Research Section
Lisa C. Cicutto, RN, PhD, Head

Division of Environmental and Occupational Health Sciences
Lisa A. Maier, MD, MSPH, Chief

Division of Gastroenterology
Richard J. Martin, MD, Acting Chief

Hospital and Internal Medicine Section
Carrie A. Horn, MD, Head

Division of Mycobacterial and Respiratory Infections
Charles L. Daley, MD, Chief
Michael D. Iseman, MD (Emeritus)

Nephrology/Diabetology Section
Elizabeth F. Owen Kern, MD, MS, Head

Neuropsychology Section
Sarah B. Viamonte, PhD, Head

Division of Oncology, Cancer Center
Jeffrey A. Kern, MD, Chief

Division of Pathology
Steve D. Groshong, MD, PhD, Chief

Critical Care Section
Kenneth Lyn-Kew, MD, Head

Division of Rheumatology
Kevin K. Brown, MD, Acting Chief

DEPARTMENT OF RADIOLOGY
Debra S. Dyer, MD, Chair

DEPARTMENT OF BIOMEDICAL RESEARCH
Philippa Marrack, PhD, Chair

DEPARTMENT OF PEDIATRICS
Erwin W. Gelfand, MD, Chair

Pulmonary
David P. Nichols, MD, Head

Allergy & Clinical Immunology Division
Donald Y. M. Leung, MD, PhD, Head

Ambulatory Pediatrics
Pia J. Hauk, MD, Head

Behavioral Health
Bruce G. Bender, PhD, Head

Cell Biology
David W.H. Riches PhD, Head

CHIEF MEDICAL OFFICER
Stephen K. Frankel, MD

Division of Biostatistics and Bioinformatics
Douglas C. Everett, PhD, Head

Center for Genes, Environment and Health
Tasha E. Fingerlin, PhD, Director
Faculty Leadership

DIVISION OF PULMONARY, CRITICAL CARE AND SLEEP MEDICINE
Irina Petrache, MD, Chief
Evgeny Berdyshev, PhD
David A. Beuther, MD
Michelle A. Beutz, MD
Russell P. Bowler, MD, PhD
Reuben M. Cherniack, MD
Hong Wei Chu, MD
Gregory P. Cosgrove, MD
Gary R. Cott, MD
Vanessa Craig, MD
James D. Crapo, MD
Gregory P. Downey, MD
Evans Fernandez-Perez, MD, MS
James J. Fenton, MD
Stephen K. Frankel, MD
Anthony N. Gerber, MD, PhD
James T. Good, MD
Kendra Hammond, MD
Tristan Huie, MD
Yoko Ito, MD, PhD

William J. Janssen, MD
Rebecca Keith, MD
Susan Kotake, MD
Esther L. Langmack, MD
Robert Lapidus, MD
Steven E. Lommatsch, MD
Barry J. Make, MD
Kenneth Malcolm, PhD
Laurie Manka, MD
Robert J. Mason, MD
Robert M. Maulitz, MD
Richard D. Mountain, MD
Mari Numata-Nakamura, MD, PhD
Jerry A. Nick, MD
Amy L. Olson, MD, MSPH
William T. Pluss, MD
Donald R. Rollins, MD
Jennifer Taylor-Cousar, MD
Milene T. Saavedra, MD
Robert A. Sandhaus, MD, PhD
Sarah Sasse, PhD
Kelly Schweitzer, PhD
Karina Serban, MD
Daniel R. Smith, MD
Evan L. Stepp, MD
Jeffery J. Swigris, DO, MS
David A. Taryle, MD
Dennis R. Voelker, PhD
Zulma X. Yunt, MD
Rachel L. Zemans, MD
Michael E. Wechsler, MD, PhD
James P. Woodrow, MD
Qun Wu, MD, PhD

Critical Care Section
Kenneth Lyn-Kew, MD, Head
Charlene E. Brady, MD
Matthew Cohn, MD
Luciano Lemos-Filho, MD, MMSc
Sherstin T. Lommatsch, MD
Vipin Malik, MD
Jason McCarl, MD
Dionne Morgan, MD
James O’Brien, MD
Ahmad Rashid, MD
Michael D. Schwartz, MD
Elaine M.K. Schwartz, MD
Amen Sergew, MD
Joshua J. Solomon, MD, MSPH
Peter Stubenrauch, MD
Mary L. Warner, MD
Jennifer S. Wink, MD

Sleep Medicine Section
Mark Aloia, PhD
Jack D. Edinger, PhD
Teofilio L. Lee-Chiong, MD
Sheila Tsai, MD

Tasha E. Fingerlin, PhD
Lisa A. Maier, MD, MSPH

Faculty Leadership

National Jewish Health
Selected 2015 Publications

National Jewish Health faculty publish more than 300 articles each year in peer-reviewed scientific journals. Below is a selection of leading articles from the past year.


BREAKTHROUGHS IN RESEARCH

National Jewish Health has advanced the understanding of medicine with key scientific discoveries. A few of these important advances are listed below.

IgE. The molecule responsible for allergic reactions. This discovery has become the basis for many new treatments for asthma and allergies.

The T-cell receptor gene. Plays a crucial role in recognizing foreign invaders and orchestrating an immune response. It opened the door to understanding how bodies fight viruses, bacteria and cancer.

Superantigens. Extremely powerful bacterial toxins associated with particularly virulent diseases, such as toxic shock syndrome and Legionnaire’s disease.

Combined chemotherapy for tuberculosis. National Jewish Health physicians were among the leaders in developing this crucial tool for fighting tuberculosis.

Mechanisms of apoptosis. Pioneering efforts have helped doctors understand how the body effectively removes and recycles up to two billion cells a day and resolves inflammation in the lung.

Allergies to artificial joints. Researchers have developed a blood test that can detect allergy to nickel used in artificial joints, a common cause of failure.

RECOGNITION

National Jewish Health is the only hospital with a primary focus on pulmonary and related diseases. We are now at 25 locations in Colorado and at the Mount Sinai — National Jewish Health Respiratory Institute in New York City.

National Jewish Health has been ranked by U.S. News & World Report as number 1 or 2 every year that the pulmonology category has been included in the rankings (since 1997).

U. S. News & World Report rated the COPD care provided at National Jewish Health as “high performing,” the highest rating possible.

National Jewish Health has 30 doctors named as “America’s Top Doctors” by Castle Connolly, including 13 in Pulmonary Disease (most in the nation in this category).

National Jewish Health is in the top 6 percent of institutions in the country funded by the NIH, in terms of absolute dollars.
FOCUS, EXPERIENCE, COLLABORATION

With a 117-year history of transformative medicine, National Jewish Health is the only organization of its kind in the world dedicated exclusively to respiratory and related diseases. Today, National Jewish Health has an unparalleled pulmonary expertise, with internationally recognized physician-scientists bringing their extensive experience and knowledge to many of the most challenging respiratory cases in the nation. Pulmonologists work closely with their colleagues in cardiology, gastroenterology, allergy, immunology, oncology and radiology to understand the whole person and find solutions for our patients.

How to reach us?
Call our Physician Line at 800.652.9555.
Or learn more at njhealth.org.